The median global prevalence of EGFR in the advanced stage of NSCLC was 33.07%58 while 47% of Asians showed EGFR mutations.57 The latest data on EGFR mutations in Indonesia also revealed EGFR mutations in 44.4% of 1874 cytological specimens diagnosed with EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.